High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.
Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.
Pretreatment interstitial lung disease (ILD) is a significant risk factor for symptomatic and severe radiation pneumonitis in patients with stage I non-small cell lung cancer (NSCLC) who are treated with stereotactic body radiation therapy (SBRT) alone, according to a new study.
Few patients with HCC are candidates for curative treatment at diagnosis. However, a new study demonstrated that stereotactic body radiotherapy…
